These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2956863)

  • 1. Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite.
    Okerholm RA; Chan KY; Lang JF; Thompson GA; Ruberg SJ
    Am J Cardiol; 1987 Aug; 60(5):21C-26C. PubMed ID: 2956863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacology and pharmacokinetics of enoximone].
    Jähnchen E; Trenk D
    Z Kardiol; 1991; 80 Suppl 4():21-6. PubMed ID: 1833893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure.
    Ruder MA; Lebsack C; Winkle RA; Mead RH; Smith N; Kates RE
    J Clin Pharmacol; 1991 Aug; 31(8):702-8. PubMed ID: 1831816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral enoximone pharmacokinetics in patients with congestive heart failure.
    Lima JJ; Leier CV; Holtz L; Sterechele J; Shields BJ; MacKichan JJ
    J Clin Pharmacol; 1987 Sep; 27(9):654-60. PubMed ID: 2960700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation.
    Khalife K; Zannad F; Brunotte F; Belhadj K; Juilliere Y; Iannascoli F; Gilgenkrantz JM
    Am J Cardiol; 1987 Aug; 60(5):75C-79C. PubMed ID: 2956874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of fenoximone, a new cardiotonic, in healthy subjects.
    Alken RG; Belz GG; Haegele KD; Meinicke T; Schechter PJ
    Clin Pharmacol Ther; 1984 Aug; 36(2):209-16. PubMed ID: 6235081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and pharmacokinetics of enoximone.
    Dage RC; Okerholm RA
    Cardiology; 1990; 77 Suppl 3():2-13; discussion 27-33. PubMed ID: 2148277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low dose enoximone for chronic congestive heart failure.
    Jessup M; Ulrich S; Samaha J; Helfer D
    Am J Cardiol; 1987 Aug; 60(5):80C-84C. PubMed ID: 2956875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-response study of intravenous enoximone in congestive heart failure.
    Erbel R; Meyer J; Diefenbach C; Delorme G; Bourdarias JP; Vernant P; Lellouche D; Mattioli G; Barbieri A; Installe E
    Am J Cardiol; 1987 Aug; 60(5):31C-36C. PubMed ID: 2956865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
    Uretsky BF; Valdes AM; Reddy PS
    Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of intravenous enoximone: pharmacodynamics and pharmacokinetics in patients with heart failure.
    Smith NA; Kates RE; Lebsack C; Ruder MA; Mead RH; Bekele T; Okerholm RA; Rubin GM; Winkle RA
    Am Heart J; 1991 Sep; 122(3 Pt 1):755-63. PubMed ID: 1831585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study.
    Gilbert EM; Bristow MR; Mason JW
    Am J Cardiol; 1987 Aug; 60(5):57C-62C. PubMed ID: 2956870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinico-pharmacologic aspects of therapy with enoximone].
    Trenk D; Jähnchen E
    Z Kardiol; 1994; 83 Suppl 2():7-14. PubMed ID: 8091828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intravenous enoximone in dialysis patients.
    Fiegel P; Trenk D; Jaehnchen E; Dieterich HA
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S20-3. PubMed ID: 2480480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of chronic cardiac insufficiency with intravenous bolus enoximone. Study of a pharmacokinetic-hemodynamic relation].
    Gibelin P; Garraffo R; Sbirrazzuoli V; Lapalus P; Morand P
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():75-81. PubMed ID: 2147839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with oral enoximone for chronic congestive heart failure: the European experience.
    Treese N; Erbel R; Pilcher J; Choraria S; Rhein S; Dieterich HA; Meyer J
    Am J Cardiol; 1987 Aug; 60(5):85C-90C. PubMed ID: 2956876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease--relation to plasma concentration.
    Mitrovic V; Petrovic O; Bahavar H; Neuzner J; Dieterich HA; Schlepper M
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):689-95. PubMed ID: 1832289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential hemodynamic effects of oral enoximone in severe congestive heart failure.
    Murali S; Uretsky BF; Betschart AR; Tokarczyk TR; Kolesar JA; Reddy PS
    Am J Cardiol; 1990 Feb; 65(7):515-9. PubMed ID: 2137668
    [No Abstract]   [Full Text] [Related]  

  • 19. [Continuous enoximone infusion in patients with severe heart failure in dilated cardiomyopathy, hemodynamic, neurohumoral, chemical laboratory and clinical results].
    Neuzner J; Mitrovic V; Pitschner HF; Lissmann H; Schlepper M
    Z Kardiol; 1991 Jun; 80(6):397-403. PubMed ID: 1681628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT; Janicki JS; Jain MC
    J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.